Page last updated: 2024-11-07

4-carboxyfluorescein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID123755
CHEBI ID51617
SCHEMBL ID20095
MeSH IDM0131398

Synonyms (39)

Synonym
BIDD:GT0758
5-carboxyfluorescein, 99% (hplc)
3',6'-dihydroxy-3-oxo-3h-spiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid
4-carboxyfluorescein
76823-03-5
spiro(isobenzofuran-1(3h),9'-(9h)xanthene)-5-carboxylic acid, 3',6-dihydroxy-3-oxo-
4(5)-carboxyfluorescein
5-carboxyfluorescein ,
CHEBI:51617
5-fam
5-carboxyfluorescein, bioreagent, suitable for fluorescence, >=95% (hplc)
3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylic acid
C2477
spiro[isobenzofuran-1(3h),9'-[9h]xanthene]-5-carboxylicacid, 3',6'-dihydroxy-3-oxo-
unii-ab2mm66gsf
ab2mm66gsf ,
BP-30031
AKOS015901359
FT-0620190
3',6'-dihydroxy-3-oxo-3h-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylic acid
HY-66022
SCHEMBL20095
DTXSID30227642
J-100059
AC-32459
mfcd00036874
BCP22613
SY057359
NJYVEMPWNAYQQN-UHFFFAOYSA-N
Q27122687
AS-32304
5 - fam
5-carboxyfluorescein; 3',6'-dihydroxy-3-oxo-spiro[isobenzofuran-1(3h),9'-[9h]xanthene]-5-carboxylic acid
spiro(isobenzofuran-1(3h),9'-(9h)xanthene)-5-carboxylic acid, 3',6'-dihydroxy-3-oxo-
3',6'-dihydroxy-3-oxospiro(isobenzofuran-1(3h),9'-(9h)xanthene)-5-carboxylic acid
PD012213
5(6)-carboxyfluorescein, mixed isomers
Z1139186537
3',6'-dihydroxy-3-oxo-spiro[isobenzofuran-1,9'-xanthene]-5-carboxylic acid

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"In this study, capillary electrophoresis (CE) combined with HPLC-MS/MS were used as a powerful platform for screening of inhibitors of mammalian target of rapamycin (mTOR) in natural product extracts."( Screening of mammalian target of rapamycin inhibitors in natural product extracts by capillary electrophoresis in combination with high performance liquid chromatography-tandem mass spectrometry.
Kang, J; Li, F; Li, M; Zhang, Y, 2015
)
0.42
" Patients undergoing hematopoietic stem cell transplantation (HSCT) are exposed to various types of drugs, and understanding how these drugs interact is of the utmost importance."( Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions.
Andersson, BS; Hassan, M; Valdez, BC, 2017
)
0.46
" Clinically significant drug interactions can be induced by organic anion transporter 1 (OAT1) and OAT3 when concomitant medications competitively interact with the transporters."( Sensitive and valid assay for reliable evaluation of drug interactions mediated by human organic anion transporter 1 and 3 using 5-carboxyfluorescein.
Chae, YJ; Chang, JE; Lee, KR, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" Hence, infection and inflammatory diseases may impose variability in drug bioavailability through alterations in the intestinal expression and activity of drug transporters and metabolic enzymes."( Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats.
Brocks, DR; Kalitsky-Szirtes, J; Piquette-Miller, M; Shayeganpour, A, 2004
)
0.32
" Hence, infection and inflammatory diseases may induce variability in drug bioavailability through alterations in the intestinal expression and activity of drug transporters."( Suppression of efflux transporters in the intestines of endotoxin-treated rats.
Hatanaka, M; Hayashi, M; Kai, T; Kanbayashi, A; Murata, H; Nakaike, M; Takizawa, Y; Tanaka, A; Tomita, M, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fluorochromeA fluorescent dye used to stain biological specimens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (113)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (9.73)18.7374
1990's17 (15.04)18.2507
2000's27 (23.89)29.6817
2010's48 (42.48)24.3611
2020's10 (8.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.09 (24.57)
Research Supply Index4.76 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (0.86%)4.05%
Observational0 (0.00%)0.25%
Other115 (99.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]